Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden

Granstam, Elisabet ; Westborg, Inger ; Barkander, Anna ; Börjesson, Malin ; Lindahl, Sara ; Meszaros, Eva ; Wojciechowska-Zajac, Anna ; Wagner, Philippe LU ; Albrecht, Susanne and Karlsson, Niklas , et al. (2016) In Acta Ophthalmologica 94(7). p.646-651
Abstract

Purpose: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. Methods: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. Results: The rate of referral due to AMD was significantly reduced during the time period (−48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (−0.01,... (More)

Purpose: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. Methods: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. Results: The rate of referral due to AMD was significantly reduced during the time period (−48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (−0.01, SD 0.37; p < 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p < 0.001). Conclusion: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
anti-vascular endothelial growth factor, low vision clinics, Swedish Macula Register, wet AMD
in
Acta Ophthalmologica
volume
94
issue
7
pages
6 pages
publisher
Wiley-Blackwell
external identifiers
  • pmid:27545047
  • wos:000386631400021
  • scopus:84991585512
ISSN
1755-375X
DOI
10.1111/aos.13187
language
English
LU publication?
yes
id
83c13585-1756-44ff-9740-3f2e198ff472
date added to LUP
2016-11-07 13:11:44
date last changed
2024-01-04 15:50:47
@article{83c13585-1756-44ff-9740-3f2e198ff472,
  abstract     = {{<p>Purpose: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. Methods: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients &gt;65 years of age in five northern counties were included in the survey. Results: The rate of referral due to AMD was significantly reduced during the time period (−48%; p &lt; 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (−0.01, SD 0.37; p &lt; 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p &lt; 0.001). Conclusion: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.</p>}},
  author       = {{Granstam, Elisabet and Westborg, Inger and Barkander, Anna and Börjesson, Malin and Lindahl, Sara and Meszaros, Eva and Wojciechowska-Zajac, Anna and Wagner, Philippe and Albrecht, Susanne and Karlsson, Niklas and Bjärnhall, Gunilla and Lövestam, Adrian Monica}},
  issn         = {{1755-375X}},
  keywords     = {{anti-vascular endothelial growth factor; low vision clinics; Swedish Macula Register; wet AMD}},
  language     = {{eng}},
  month        = {{11}},
  number       = {{7}},
  pages        = {{646--651}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Acta Ophthalmologica}},
  title        = {{Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden}},
  url          = {{http://dx.doi.org/10.1111/aos.13187}},
  doi          = {{10.1111/aos.13187}},
  volume       = {{94}},
  year         = {{2016}},
}